Large Molecule Bioanalysis done differently

To help you achieve more.

BioAgilytix has evolved the model for partnership in large molecule bioanalysis to benefit our customers and the patients they serve.

Services Delivered Scientist to Scientist

Our fully integrated GxP services are driven by your assay requirements and delivered by our veteran scientists – collaboratively, accurately, and on time.

biomarkers

Biomarkers

immunogenicity

Immunogenicity

pharmacokinetics

Pharmacokinetics (PK)

cell-based-assays

Cell-Based Assays

Solutions Enabled by World-Leading Expertise

Our team is comprised of recognized experts in effectively navigating complex and evolving opportunities for biotherapeutics innovation.

biosimilars

Biosimilars

gene-therapy

Gene Therapy

antibody-drug-conjugates

Antibody Drug Conjugates (ADCs)

immuno-oncology

Immuno-oncology

The Bioagilytix Perspective

Explore the BioAgilytix way of thinking. Visit our Resource Center to learn more about our scientists’ expertise through case studies, blogs, industry articles and other scientific resources.

resource center

Visit Resource Center

usa europe labs

Advanced facilities to support all phases of large molecule global studies.

    LinkedIn Company Updates

  • 1 Day Agoview on linkedin

    BioAgilytix

    Our scientists have decades of experience supporting biosimilar studies with ligand binding assays, characterization, and stability testing on multiple platforms. As such, they frequently contribute to industry publications on the topic. Read more here: https://lnkd.in/emYVQQD

  • 1 Day Agoview on linkedin

    BioAgilytix

    When you join BioAgilytix, you become part of a collaborative, international team of people who are equally passionate about and committed to advancing bioanalytical innovation. Explore our career opportunities today get started! 

  • 2 Days Agoview on linkedin

    BioAgilytix

    Even with all the success of CAR-T therapy, it is essential to consider the potential release of elicit cytokine release syndrome (CRS) cytotoxicity. Read about how BioAgilytix handles testing for this unwanted release of cytokines in our latest blog post from Global Chief Scientific Officer, Dr.Afshin Safavi, Ph.D. https://lnkd.in/eughsVa